Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain

Brain Research

Volumn 867, Issue 1-2, 2000, Pages 52-61

  Farooqui, Shakeel M ^a   Zhang, Kehong ^a   Makhay, Malath ^a   Jackson, Keasha ^a   Farooqui, Shiru Q ^a   Cherry, James A ^b   O'Donnell, James M ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b USA   (United States)

Author keywords

6 OHDA; cAMP dependent phosphodiesterase; Cerebellum; Hypothalamus; Neostriatum; Noradrenergic lesions; PDE4; Rolipram; Western blotting, RT PCR

Indexed keywords

CYCLIC AMP; DESIPRAMINE; PHOSPHODIESTERASE IV;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC DENERVATION; BRAIN INJURY; CEREBELLUM; CORRELATION FUNCTION; ENZYME ACTIVITY; HYPOTHALAMUS; MALE; NEOSTRIATUM; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTIBODIES; BRAIN; BRAIN CHEMISTRY; CEREBELLUM; CYCLIC AMP; DESIPRAMINE; DOPAMINE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; MALE; NEOSTRIATUM; NERVE TISSUE PROTEINS; NOREPINEPHRINE; OXIDOPAMINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SIGNAL TRANSDUCTION; SYMPATHOLYTICS;

EID: 0034625493     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02224-1     Document Type: Article

References (38)

1. Alvarez R., Sette C.Y., Eglen R.M., Wilhem R., Shelton E.R., Conti M. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE4D3. Mol. Pharmacol. 48:1995;616-622.
2. Balaban C.D., Billingsley M.L., Kinacid R.L. Evidence for transynaptic regulation of calmodulin-dependent cyclic nucleotide phosphodiesterase in cerebellar purkinje cells. J. Nueorosci. 9:1989;2374-2381.
3. Beavo J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiologi. Rev. 75:1995;725-748.
4. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
5. Bolger G.B. Molecular biology of cyclic nucleotide phosphodiesterases: A diverse family of regulatory enzymes. Cell Signal. 6:1994;851-859.
6. Bolger G.B., Micheali T., Martins T., St. John T., Steiner B., Rodger L., Riggs M., Wigler M., Furguson K. A family of human phosphodiesterase homologuues to the dunce learning and memory gene product of drosophila melanogaster are potential targets for antidepressent drugs. Mol. Cell. Biol. 13:1993;6558-6571.
7. Breese G.R., Taylor T.D. Depletion of brain noradrenaline and dopamine by 6-hydroxydopmaine. Br. J. Pharmacol. 42:1971;88-99.
8. Bushnik T., Conti M. Role of multiple cAMP-specific phosphodiesterase variants. Biochem. Soc. Trans. 276:1997;1014-1019.
9. Cherry J.A., Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated reinforcement, movement and affect. J. Comp. Neurol. 407:1999;287-301.
10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium isothiocynate-phenol-choloroform extraction. Anal. Biochem. 162:1987;156-159.
11. Conti M., Iona S., Cuomo M., Swinnen V.J., Odeh J., Svoboda M.E. Characterization of a hormone-induced high affinity adenosine 3′-5′ cyclic monophosphodiesterase from the rat Sertoli cell. Biochemistry. 34:1995;7979-7987.
12. Costrzewa R.M., Jacobowitz D.M. Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 26:1974;199-288.
13. Davis R.L., Takayasu H., Eberwine M., Myers J. Cloning and characterization of mammalian homologs of the Drosophila dunce+ gene. Proc. Natl. Acad. Sci. USA. 86:1989;3604-3608.
14. Engels P., Fichtel K., Lubbert H. Expression and regulation of human and rat phosphodiesterae type IV isogenes. FEBS Lett. 350:1994;291-295.
15. Engels P., Abdel-Al P., Hulley P., Lubbert H. Brain distribution of four rat homologues of the Drosophila Dunce cAMP phosphodiesterase. J. Neurosci. Res. 41:1995;169-178.
16. Farooqui S.M., Brock J.F., Onaivi E.S., Hamdi A., Prasad C. Differential modulation of dopaminergic systems in the rat brain by dietary protein. Neurochem. Res. 19:1994;167-176.
17. Giembycz M.A. Phosphodiesterase 4 and tolerance to beta adrenergic receptor agonists in asthma. Trends Pharmacol. Sci. 17:1996;331-336.
18. Giembycz M.A., Corrigan C.J., Seybold J., Newton R., Barnes P.J. Identification of phosphodiesterase 3, 4 and 7 in human CD4+ and CD8+ T lymphocytes: Role in regulating proliferation and biosynthesis of interleukin 2. Brit. J. Pharmacol. 118:1996;1945-1958.
19. Herve D., Trovero F., Blanc G., Vezina P., Glowinski J., Tassin J.P. Involvement of dopamine neurons in the regulation of beta adrenergic receptor sensitivity in rat prefrontal cortex. J. Neurochem. 54:1990;1864-1869.
20. Iona S., Cuomo M., Bushnik T., Naro F., Sette C., Hess M., Shelton E.R., Conti M. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Molec. Pharmacol. 53:1998;23-32.
21. Loughney K., Ferguson K. Identification and quantification of PDE isozymes and subtypes by molecular biological methods. Schudt C., Dent G., Rabe K.F. Phosphodiesterase Inhibitors. 1996;1-19 Academic Press, San Diego.
22. Manning C.D., McLaughlin M., Livi G.P., Cieslinski L.B., Torphy T.J., Barnette M.S. Prolonged beta adrenergic stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J. Pharmacol. Exp. Therap. 276:1996;810-818.
23. McPhee L. Pooley, M. Lobban, G. B. Bolger, M. D. Housaly, Identification, characterization and regional distribution of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem. J. 310:(RNPDE4A5):1995;965-974.
24. O'Donnell J.M. Effects of inhibitors of cyclic AMP phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther. 264:1993;1168-1178.
25. O'Donnell J.M., Frith S. Behavioral effects of family-selective inhibitors of phosphodiesterase. Pharmacol. Biochem. Behav. 63:1999;185-192.
26. Ordway G.A. Effect of noradrenergic lesions on subtype of a2 adrenergic receptors in rat brain. J. Neurochem. 64:1995;1118-1126.
27. Ordway G.A., O'Donnell J.M., Frazer A. Effect of clenbuterol on central beta-1 and beta-2 adrenergic receptors of the rat. J. Pharm. Expt. Ther. 241:1987;187-195.
28. Sette C., Iona S., Conti M. The short-term activation of a rolipram-sensitive, cAMP phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cyclic AMP dependent phosphorylation. J. Biol. Chem. 269:1994;9245-9252.
29. Shakur Y., Wilson M., Pooley L., Lobban M., Grifith S.L., Campbell A.M., Beattie J., Daly C., Houslay M.D. Identification and characterization of the type-IVA cyclic AMP specific phosphodiesterase RD1 as a membrane bound protein expressed in cerebellum. Biochem. J. 306:1995;801-809.
30. Swinnen J.V., Joseph R.D., Conti M. Molecular cloning of rat homologes of the Drosophila melanogaster dunce cAMP phosphodiesterase: Evidence for a family of genes. Proc. Natl. Acad. Sci. USA. 86:1989;5325-5329.
31. Swinnen J.V., Tsikalas K.E., Conti M. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem. 266:1991;18370-18377.
32. Torphy J., Undem B.J. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax. 46:1991;512-523.
33. Torphy T.J., Zhou H., Cieslinski L.B. Stimulation of beta adrenergic receptors in human monocyte cell line (U937) up-regulates cyclic AMP specific phosphodiesterase activity. J. Pharmacol. Exp. Therap. 263:1992;1195-1202.
34. Torphy T.J., Zhou H., Foley J., Sarau H.M., Manning C.D., Barnette M.S. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. J. Biol. Chem. 270:1995;23598-23604.
35. Ye Y., O'Donnell M.J. Diminished noradrenergic activity in the brain down-regulates type 4 phosphodiesterase in rat cerebral cortex. J. Neurochem. 66:1996;1894-1902.
36. Ye Y., Conti M., Houslay M.D., Farooqui S.M., Chen M., O'Donnell J.M. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, High-affinity cyclic phosphodiesterase (PDE4) in rat brain. J. Neurochem. 69:1997;2397-2404.
37. Zhang K., Farooqui S.M., Jackson K.T., O'Donnell M.J. Regulation of the development of rolipram-sensitive, low cyclic AMP specific phosphodiesterase in rat brain. Dev. Brain Res. 116:1999;181-189.
38. Zhang K., Farooqui S.M., O'Donnell M.J. Ontogeny of rolipram-sensitive, low-Km cyclic AMP-sensitive phosphodiesterases in rat brain. Dev. Brain Res. 112:1999;11-19.